To further demonstrate above results, a cohort of 96 advanced HCC tissues was used to study the role of GRAMD1A in clinical progression, IHC analysis suggested GRAMD1A expression was positive in 96.9% (93/96) of examined tissues, only 3% (3/96) was negative. Here, GRAMD1A is linked to hepatocellular carcinoma.